1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The aims of this study were to investigate the short-term benefit of etanercept (ETN) + MTX vs conventional synthetic DMARDs (csDMARDs; HCQ, LEF or SSZ) + MTX in subjects with established RA. The effect of disease duration (≤2 years vs >2 years) and severity (moderate vs severe) on treatment outcomes was also assessed. Methods. Data from Asian and Latin American subjects with inadequate response to MTX were pooled from the APPEAL (ETN 25 mg biweekly + MTX or csDMARD + MTX; NCT00422227) and Latin RA (ETN 50 mg/week + MTX or csDMARD + MTX; NCT00848354) studies. Endpoints included the 28-joint DAS with ESR (DAS28-ESR) low disease activity (LDA; ≤3.2), DAS28 remission (<2.6) and HAQ score ≤0.5.

          Related collections

          Author and article information

          Journal
          Rheumatology (Oxford)
          Rheumatology (Oxford, England)
          Oxford University Press (OUP)
          1462-0332
          1462-0324
          Nov 2014
          : 53
          : 11
          Affiliations
          [1 ] Department of Medicine, Division of Rheumatology, University of Texas Southwestern Medical Center, Dallas, TX, Pfizer Inc., Collegeville, PA, USA and Pfizer Europe, Rome, Italy RFleischmann@arthdocs.com.
          [2 ] Department of Medicine, Division of Rheumatology, University of Texas Southwestern Medical Center, Dallas, TX, Pfizer Inc., Collegeville, PA, USA and Pfizer Europe, Rome, Italy.
          Article
          keu235
          10.1093/rheumatology/keu235
          24907147
          0ae0807d-2940-4e88-b6e1-e2205e16914f
          History

          sulfasalazine,hydroxychloroquine,rheumatoid arthritis,methotrexate,leflunomide,etanercept,DMARDs

          Comments

          Comment on this article